Abstract:Background: Epigenetic gene silencing is one of the major causes of carcinogenesis. Its widespread occurrence in cancer genome could inactivate many cellular pathways including DNA repair, cell cycle control, apoptosis, cell adherence, and detoxification. The abnormal promoter methylation might be a potential molecular marker for cancer management.Methods: For rapid identification of potential targets for aberrant methylation in gynecological cancers, methylation status of the CpG islands of 34 genes was determined using pooled DNA approach and methylation-specific PCR. Pooled DNA mixture from each cancer type (50 cervical cancers, 50 endometrial cancers and 50 ovarian cancers) was made to form three test samples. The corresponding normal DNA from the patients of each cancer type was also pooled to form the other three control samples. Methylated alleles detected in tumors, but not in normal controls, were indicative of aberrant methylation in tumors. Having identified potential markers, frequencies of methylation were further analyzed in individual samples. Markers identified are used to correlate with clinico-pathological data of tumors using chi(2) or Fisher's exact test.Results: APC and p16 were hypermethylated across the three cancers. MINT31 and PTEN were hypermethylated in cervical and ovarian cancers. Specific methylation was found in cervical cancer (including CDH1, DAPK, MGMT and MINT2), endometrial cancer (CASP8, CDH13, hMLH1 and p73), and ovarian cancer (BRCA1, p14, p15, RIZ1 and TMS1). The frequencies of occurrence of hypermethylation in 4 candidate genes in individual samples of each cancer type (DAPK, MGMT, p16 and PTEN in 127 cervical cancers; APC, CDH13, hMLH1 and p16 in 60 endometrial cancers; and BRCA1, p14, p16 and PTEN in 49 ovarian cancers) were examined for further confirmation. Incidence varied among different genes and in different cancer types ranging from the lowest 8.2% (PTEN in ovarian cancer) to the highest 56.7% (DAPK in cervical cancer). Aberrant methylation for some genes (BRCA1, DAPK, hMLH1, MGMT, p14, p16, and PTEN) was also associated with clinico-pathological data.Conclusion: Thus, differential methylation profiles occur in the three types of gynecologic cancer. Detection of methylation for critical loci is potentially useful as epigenetic markers in tumor classification. More studies using a much larger sample size are needed to define the potential role of DNA methylation as marker for cancer management.

Methylation Profiles of 22 Candidate Genes in Breast Cancer Using High-Throughput MALDI-TOF Mass Array

Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients

Hypermethylation of Tumor Suppressor Genes Involved in Critical Regulatory Pathways for Developing A Blood-Based Test in Breast Cancer

Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients

Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer

Differential Methylation Relative to Breast Cancer Subtype and Matched Normal Tissue Reveals Distinct Patterns

High-throughput Hacking of the Methylation Patterns in Breast Cancer by in Vitro Transcription and Thymidine-Specific Cleavage Mass Array on MALDI-TOF Silico-Chip.

Methylation Signature of Lymph Node Metastases in Breast Cancer Patients.

Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers

Differential DNA Methylation Profiles in Gynecological Cancers and Correlation with Clinico-Pathological Data

Circulating Methylated DNA As Biomarkers for Cancer Detection

Aberrant Promoter Methylation of Cancer-Related Genes in Human Breast Cancer

DNA Methylation Profiles and Their Diagnostic Utility in BC

DNA Methylation and Breast Cancer Risk: An Epigenome-Wide Study of Normal Breast Tissue and Blood

DNA methylation as a biomarker in breast cancer

Discovered Key CpG Sites by Analyzing DNA Methylation and Gene Expression in Breast Cancer Samples

Identification of Aberrantly Methylated Differentially Expressed Genes in Breast Cancer by Integrated Bioinformatics Analysis

Identification of Methylation Markers and Differentially Expressed Genes with Prognostic Value in Breast Cancer.

Integrative analysis of DNA methylation and gene expression profiles identified potential breast cancer-specific diagnostic markers

DNA methylation signatures provide novel diagnostic biomarkers and predict responses of immune therapy for breast cancer

The Identification of Specific Methylation Patterns across Different Cancers